Ici Australia Limited

Biota Scientific Management Pty Ltd

The Walter and Eliza Hall Institute of Medical Research

Genentech, Inc.

Imperial Chemical Industries Limited

Abbott Laboratories Corporation

Abbvie Inc.

Ici Australia Operations Proprietary Limited

St. Vincent's Institute of Medical Research

Howard Florey Institute

Biota Scientific Managment Pty Ltd

Ci Australia Ltd.

The Walter and Eliza Hall Medical Research Institute

Keith G Watson

Graeme J Farquharson

Graham J Bird

Alexander Serban

Guy Y Krippner

Darryl McConnell

Pauline Stanislawski

Wen-Yang Wu

Lindsay E Cross

Guillaume Laurent Lessene

Richard B Warner

Andrew J Souers

John A Flygare

Steven Elmore

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Andrew M Petros

Danette Dudley

Brad E Sleebs

Betty Jin

Chinh Thien Bui

Brian John Smith

Peter Colman

Peter Edward Czabotar

George Nikolakopoulos

Simon P Tucker

Phillip A Reece

Carl Steven Rye

Richard J Conway

Lynette A Garson

Craig G Lovel

Antony Wilks Burgess

Siew Yeen Chai

Stephen E Shanahan

Simon J F MacDonald

Derek Anthony Demaine

Michael William Parker

Frederick A O Mendelsohn

Francesca Walker

Helen Witchard

Anthony Lloyd Albiston

Grame J Farquharson

Graham G A Inglis

Xilu Wang

Le Wang

Zhi-Fu Tao

Lisa A Hasvold

John E Barton

Bruce Adam Forsyth

Kurt Deshayes

Colin Wilshire

Stephen Bell

Peter Drygala

Linsay E Cross

Wayne Best

Timothy L Houston

Peter G Tucker

John D Wishart

Murray L Whitelaw

This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.

Antiviral agents

The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.

Anti-cancer agents

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. 

The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; Ris acetyl or trifluoroacetyl; and n is an integer from 10 to 18 or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a viral infection.

Dimeric compounds and their use as anti-viral agents

Growing community of inventors

Box Hill North, Australia

Keith G Watson